Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Carboplatin + Durvalumab + Paclitaxel |
Indication/Tumor Type | endometrial cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | endometrial cancer | predicted - sensitive | Carboplatin + Durvalumab + Paclitaxel | Phase III | Actionable | In a Phase III trial (DUO-E), Imfinzi (durvalumab) plus platinum therapy (carboplatin/paclitaxel) followed by Imfinzi (durvalumab) with (n=150) or without Lynparza (olaparib) (n=170) maintenance resulted in an improved progression-free survival compared to platinum therapy + placebo followed by placebo maintenance (n=163) (HR=0.42 with olaparib, HR=0.63 without olaparib) in a subgroup of CD274 (PD-L1)-positive patients with advanced or recurrent endometrial cancer (PMID: 37864337; NCT04269200). | 37864337 |
PubMed Id | Reference Title | Details |
---|---|---|
(37864337) | Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. | Full reference... |